2013

Tan, D.S.P., Yap, T.A., Hutka, M., Roxburgh, P., Ang, J., Banerjee, S., Grzybowska, E., Gourley, C., Gore, M.E., and Kaye, S.B. (2013) Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer, 49 (6). pp. 1246-1253. ISSN 0959-8049 (doi:10.1016/j.ejca.2012.11.016)

Roxburgh, P., Hock, A.K., Dickens, M.P., Mezna, M., Fischer, P.M., and Vousden, K.H. (2013) Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis, 34 (3). pp. 791-798. ISSN 0143-3334 (doi:10.1093/carcin/bgs092)

2011

Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17 (3). pp. 581-588. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-10-2159)

Roxburgh, P., Reed, N., and Glasspool, R. (2011) Experience of weekly carboplatin and paclitaxel in treatment resistant ovarian cancer. European Journal of Clinical and Medical Oncology, 3 (4). ISSN 1759-8958

2010

Gourley, C. et al. (2010) Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology, 28 (15). pp. 2505-2511. ISSN 0732-183X (doi:10.1200/JCO.2009.25.1082)

2008

Roxburgh, P, and Evans, TR (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25 (11). pp. 1089-1104. ISSN 0741-238X (doi:10.1007/s12325-008-0113-z )